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Introduction
Osteopontin is a highly glycosylated serine/threonine phosphoprotein found in plasma and in extracellular matrix. It functions as a pro-inflammatory cytokine at sites of inflammation and is also implicated in bone remodeling (1, 2) . OPN is expressed by many different cell types including macrophages, natural killer cells, and activated T lymphocytes (3, 4, 5, 6) . Recently several groups have shown that there is local production of OPN in human rheumatoid arthritic joints (7, 8, 9, 10) .
Rheumatoid arthritis (RA) is a chronic, debilitating autoimmune inflammatory joint disease with complex pathophysiology. RA is characterized by the infiltration of inflammatory cells into the joint space leading to invasive growth of synovial tissue (pannus) and destruction of cartilage and bone (11) . Recently, several independent groups have suggested that osteopontin plays an essential role in RA (7, 12, 8) .
Osteopontin contains an Arg-Gly-Asp (RGD) sequence ( Fig. 1 ) that mediates its binding to multiple integrins including oc v P3 (the vitronectin receptor) on the surface of osteoclasts. It also contains a CD44-binding domain for bone matrix interactions important in bone remodeling (13) . OPN is an inflammatory cytokine that has been shown to induce cell attachment (14) and chemotaxis (15) OPN also has an integrin-binding motif that is only exposed after its cleavage by thrombin ( Fig. 1 & Fig. 2 ). This cryptic motif is the short peptide sequence SVVYGLR (in human OPN) and SLAYGLR (in mouse OPN) which interacts with a 4 pi (16, 17, 18) and a 9 Pi integrins (19, 20) . a 4 (3i otherwise known as VLA-4 or CD49d / CD29 is expressed on the surface of lymphocytes and smooth muscle cells (16, 17, 18) while agf3i is expressed on neutrophils, epithelial cells and smooth muscle cells (19, 20, 21) .
According to both Bayless (17) and Green (18) the interactions of SVVYGLR (located on the C-terminal end of the N-terminal thrombin-cleaved OPN fragment) with a 4 (3i and agPi integrins are independent of the RGD motif. 
Materials and Methods

Reagents
Human OPN Quantikine ELISA kit was purchased from R&D Systems 
To investigate significance of each amino acid within the immunogen sequence, alanine was introduced in place of each amino acid (shown in blod), and affinities of the antibodies for the mutated peptides were determined as discussed in text.
Antibodies
The antibodies were generated at Berelex Laboratories Incorporated, and were kindly donated to Dr. Lawrence Leung's Laboratory at Stanford School of Medicine, where this research was conducted. Rabbits were immunized with short peptides from the carboxyl termini of human VDTYDRGDSWYGLR (CA2001) for detection of OPN-FL; human SVVYGLR (CA1997) and mouse SLAYGLR (CA1999) for detection of OPN-R, and carboxyl termini of human SWYGL (CA1998), mouse SLAYGL (CA2000) for detection of OPN-L (Table II) . Phenyl Sepharose HP column (GE Healthcare, Pittsburgh, PA) at lml/min. Then, the column was washed until OD280 plateaued to a baseline level and a linear gradient from 4M to 2M NaCl at 1 ml/min was used to elute the proteins. 1ml fractions were collected and analyzed by SDS-page. Pure fractions were pooled and dialyzed against PBS pH 7.4.
Impure fractions were dialyzed against 4M salt and re-applied to the phenyl sepharose column until purified. The purified protein was sent out to Stanford University Beckman
Center for mass spectroscopy analysis and was confirmed as osteopontin (Data not shown).
Thrombin-cleaved OPN and thrombin / CPB-cleaved OPN preparation
To generate OPN-R, lOjig of purified milk osteopontin was digested with lOOnM of thrombin in presence of 20mM HEPES, ImM CaCl 2 , 150mM NaCl, 0.1% PEGgooo, 
Specificity determination of antibodies to OPN-FL, OPN-R and OPN-L by
Western blot 2ug of each of the three forms of osteopontin (prepared as described above), were (Table II) respectively for 1 h.
Goat anti-rabbit horse radish preoxidase-linked IgG (Jackson Immunological, West
Grove, PA) was used as secondary antibody at 1/15000 in blocking buffer for 40 min, and developed using ECL reagents (GE Healthcare, Pittsburgh, PA).
In order to determine the specificity of Anti-OPN-R and Anti-OPN-L antibodirs, after incubation with blocking buffer the two blots were each cut into three identical pieces, each piece containing a protein ladder, lOOng of OPN-F1, OPN-R and OPN-L.
Antibodies were pre-incubated with their cognate and non-cognate peptides (SWYGL and SLAYGLR) at a molar ratio of 1:50 for 2 h at room temperature before probing the membranes. The first three blots from the same gel were incubated for 1 h with Anti-OPN-R, 1:50 molar ratio of Anti-OPN-R to SLAYGLR (congnate peptide), and 1:50 molar ratio of Anti-OPN-R to SWYGL (non-cognate peptide) respectively. The second set of blots from the same gel were incubated for 1 h with Anti-OPN-L, 1:50 molar ratio of Anti-OPN-L to SWYGL (congnate peptide), and 1:50 molar ratio of Anti-OPN-L to SLAYGLR (non-cognate peptide) respectively. After incubation with the primary antibodies blots were treated as described above.
Identical 10% Nuvex polyacrylamide gel with lug of each of the three forms of OPN was run along with the Western blot gels and was stained with Bio-Safe Coomassie G250 Stain (BioRad, Hercules, CA) to not only prove purity of the purified proteins in each lane, but also as positive control for the electrophoresis.
Development of sandwich ELISAfor detection of human OPN
To detect OPN-FL from biological samples, a commercial ELISA kit (R&D Systems OPN Quantikine ELISA Kit) was used according to the manufacturer's instructions. For detection of OPN-R and OPN-L, the commercial R&D Systems OPN antibody was used to capture, and Anti-OPN-R and Anti-OPN-L antibodies were used for detection respectively. Various concentrations of the three forms of OPN ranging from 0.625ng/ml to 50ng/ml were incubated in the antibody-coated wells for 2 h at room temperature. Wells were washed three times with wash buffer (PBS, 0.05% Tween-20, pH 7.4) and were incubated with 0.5 ug/ml of the corresponding antibody for 1 h at room temperature. After three washes, goat anti-rabbit HRP-linked antibody was incubated in the wells at 1/15000 dilution for 40 min. Then, wells were washed three times and 100 ul of substrate (TMB; Alpha Diagnostic, San Antonio, TX) was added to the wells for 15 min. The reaction was stopped with 100 ul of stop solution (Alpha Diagnostic, San Antonio, TX) and read at 450 nm.
Epitope mapping of Anti-OPN-R and Anti-OPN-L antibodies
To map the epitopes for Anti-OPN-R and Anti-OPN-L antibodies, the commercial R&D Systems OPN antibody was used as the capture antibody. 10 ng/ml of milk OPN-R and OPN-L were incubated in the antibody-coated wells. Peptides ALAYGLR, SAAYGLR, SLGYGLR, SLAAGLR, SLAYALR, SLAYGAR, SLAYGLA, SLAYGLR-NH2 , RLGYALS were used to epitope-map Anti-OPN-R antibodies, and SAVYGL, SVAYGL, SWAGL, SVVYAL, SWYGA, SWYGL-NH 2 , RLGYALS were used for Anti-OPN-L antibodies (Table I) . Various molar excesses of peptides to antibodies (ranging from 1:1 to 50:1, peptide to antibody ratio) were pre-incubated for 2 h at room temperature, then were added to the wells and incubated for an additional hour. The plates were then washed three times with wash buffer and 1/15000 dilution of goat antirabbit HRP-linked antibody was incubated in the wells for 40 min. Following three washes the plates were developed as described in the previous section.
Detection ofOPN-FL, OPN-R and OPN-Lfrom RA, OA, andPsA synovial fluids byELISA
Synovial joint fluids were thawed on ice and were incubated with 3 ug/ml of HeteroBlock (Omega Biologicals, Bozeman, MT) to reduce the chance of cross-linking between capture and detection antibodies by rheumatoid factor. Following a 10 min centrifugation at 400 x g at 4°C (to clarify the samples), samples were diluted in R&D Systems ELISA kit RD1-6 assay diluent. OPN-FL in synovial fluids was detected using the R&D Systems commercial assay. OPN-R and OPN-L proteins were measured using the sandwich ELISA systems described above. Due to the wide range of OPN levels detected (ranging from 1-2 ng/ml to 50 ug/ml), median OPN levels are reported.
Statistical analysis were performed using the Wilcoxon Rank-Sum (Mann-Whitney) test with/? values less than 0.05 being considered significant. (Table III) , kindly provided by Dr. Leung, were coated onto 96-well micro black fluorescent plates at 500 ng/ml in 0.1M NaHCCb, pH 8. Sequence near the thrombin cleavage site is depicted. RGD has been mutated to RAA in some of the proteins as indicated. Vector construction, expression and purification of the proteins were performed by Dr. Timothy Myles in Dr. Leung's Laboratory and have been extensively described in reference 14.
Adhesion assay on preferential binding offibroblast-like synoviocytes to OPN-R
Adhesion assay on preferential binding offibroblast-like synoviocytes to RGDS and SWYGLR peptides
Primary cultured fibroblast-like synoviocytes were maintained as described in the previous section. 0, 0.1, 1, 10, 100, 1000 uM RGDS, GRGES, SWYGLR, and 
Results
Thrombin cleavage of milk osteopontin
To determine efficiency of thrombin cleavage of milk osteopontin, a time study was conducted. lOug of OPN was treated with lOOnM of thrombin. At various time points reaction was stopped by 200nM PPACK, and 500ng aliquots of OPN were analyzed by SDS-PAGE (Fig. 3) . Analysis of the SDS-PAGE revealed disappearance of the full-length milk OPN (55KD) and appearance of OPN-R (30KD band) and the 25KD C-terminal fragment with increasing time. It is interesting to note that after only 5 minutes of incubation with lOOnM thrombin the cleaved products are already visible.
The reaction seemed to have reached completion at 50 minutes. Therefore, to generate OPN-R for ELISA calibration curves 1 h was chosen as the ideal incubation time with lOOnM of thrombin. 
Specificity determination of antibodies Anti-OPN-R and Anti-OPN-L for OPN-R and OPN-L respectively by Western blot
Specificity of antibodies, Anti-OPN-R (CA1999) and Anti-OPN-L (CA1998)
were tested by Western blot analysis. Anti-OPN (CA2001) recognized all forms of OPN (Fig. 44) . Anti-OPN-L (CA1998) recognized human OPN-L with high degree of specificity ( Fig. 44 right panel) . The antibody raised against the mouse epitope SLAYGLR for detection of OPN-R (CA1999 or Anti-OPN-R) was found to detect both the human and mouse version of OPN-R specifically (Table II) . The antibody raised against the human version of the peptide SVVYGLR although recognized OPN-R was not as reactive as the mouse antibody. Therefore, CA1999 was used for detection of human OPN-R and CA1998 was used for detection of OPN-L for the remainder of the study. The specificity of the two antibodies were further confirmed by using the cognate and non-cognate peptides to block the antibody-antigen interactions. The peptide SLAYGLR pre-incubated with Anti-OPN-R prior to probing the membrane, blocked recognition of OPN-R by Anti-OPN-R (Fig. 48) . However, pre-incubation of the Anti-OPN-R with the non-cognate peptide at the same molar ratio did not block recognition of OPN-R by the antibody. Similarly, the peptide SVVYGL pre-incubated with Anti-OPN-L blocked recognition of OPN-L by Anti-OPN-L, but pre-incubation of the antibody with the non-cognate SLAYGLR peptide had no effect on Anti-OPN-L recognition of OPN-L (Fig. AC) . In this study the focus was on CA1998 (Anti-OPN-L) for detection of human OPN-L and CA1999 (Anti-OPN-R) for detection of human OPN-R. 
Epitope mapping ofAnti-OPN-R and Anti-OPN-L antibodies
To identify the exact epitopes of OPN-R and OPN-L recognized by Anti-OPN-R
and Anti-OPN-L antibodies respectively, a series of peptides were synthesized based on the sequence of peptides used as immunogens for generation of the antibodies (Table II) .
The cognate peptide for Anti-OPN-R was the mouse sequence SLAYGLR, and the peptide used as the immunogen for generation of Anti-OPN-L was SVVYGL. In order to identify which amino acids from the peptides are important for interaction with the respective antibodies, alanine was introduced in place of each of the amino acids in the synthesized peptides ( Table I ). The peptides were used as competitive inhibitors of the antibodies binding to OPN-R and OPN-L in the sandwich ELISA systems. The competitive inhibition assay with all peptides were done with increasing molar ratio of peptides to antibodies, but the dose dependent-curves are only depicted for the cognate and the non-cognate peptides (Fig. 1A&.C) . The rest of the peptide blocking experiments are only shown at 50:1 molar ratio of peptides to antibodies for convenience (Fig. 1B&D) .
For Anti-OPN-R antibodies, pre-incubation of the antibodies with increasing molar excess of the peptides SLAYGLR and SWYGLR inhibited the binding of the antibodies to OPN-R in a dose-dependent manner (Fig. 1A) . However, the peptides SLAYGL and SVVYGL did not interfere with binding of Anti-OPN-R antibodies to OPN-R coated plate, confirming the C-terminal arginine in the thrombin-cleaved OPN is essential for recognition of OPN-R by Anti-OPN-R. The peptides ALAYGLR, SAAYGLR, SLGYGLR effectively inhibited the binding of Anti-OPN-R, indicating that serine, leucine, and alanine residues of SLAYGLR are not essential for Anti-OPN-R recognition (Fig. IB) . On the other hand, substitution of alanine for tyrosine, second leucine, arginine, and glycine rendered the peptides SLAAGLR, SLAYGAR, SLAYGLA, and to some degree SLAYALR ineffective in inhibiting the binding of Anti-OPN-R antibodies to OPN-R. This means tyrosine, second leucine, arginine, and to some degree glycine in SLAYGLR are involved in defining the epitope for Anti-OPN-R. The epitope YGLR is shared by both human and mouse version of thrombin-cleaved OPN, which explains why Anti-OPN-R (raised against the mouse epitope SLAYGLR, and not the human epitope SVVYGLR), effectively recognizes both human and mouse OPN-R.
In addition, substituting the C-terminal carboxyl group of arginine by an amide group diminished inhibitive effect of the peptide, indicating that the carboxyl group is also essential for recognition by Anti-OPN-R.
For Anti-OPN-L antibodies, the cognate peptide SWYGL effectively blocked antibody binding in a dose-dependent manner while the peptide sequence SVVYGLR was completely ineffective (Fig. 1C) . Furthermore, the blocking studies indicated tyrosine, glycine, leucine, the C-terminal carboxyl group, and to a lesser extend the first valine in the peptide sequence SWYGL are essential in defining the epitope for Anti-OPN-L (Fig. ID) .
The blocking studies showed Anti-OPN-R and Anti-OPN-L essentially recognize three to four residues, with the C-terminal residues arginine or leucine and their carboxylates being most important for recognition by the specific antibodies. (Fig. &4) . On the other hand, OPN-R and OPN-L levels were significantly higher in RA synovial fluids when compared to OA and PsA. The median RA OPN-R level was 138.6 ng/ml compared to a 10.6 ng/ml for OA and 2.2 ng/ml for PsA (p value < 0.001), and the median OPN-L level of RA was 205.3 ng/ml compared to 25.9 ng/ml for OA and undetectable for PsA (p value < 0.006) (Fig. 8A ). There was a wide range of full-length and cleaved OPN levels in the synovial fluids of RA patients compared to OA and PsA, ranging from undetectable to more than 50 ug/ml. Such heterogeneity in OPN levels may be due to differences in stage of the disease, the particular treatment in individual patients, or other factors. The median ratio of cleaved OPN to total OPN in rheumatoid arthritis synovial fluid was 0.5, indicating that a significant amount of OPN exists in its cleaved forms within the rheumatic joint space compared to the OA and PsA (Fig. 85) . 
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Determination of preferential binding offibroblast-like synoviocytes to OPN-R
To investigate the role of thrombin-cleaved OPN in RA, adhesion of arthritic fibroblast-like synoviocytes to different forms of osteopontin was studied. Previously described wild type and RGD-mutated recombinant OPN-FL, OPN-R, and OPN-L (14) were coated onto a 96-well plate. In the RGD-mutated forms of OPN, the RGD site was To further investigate whether RGD is essential for adhesion of FLS, various amounts of RGDS peptide (ranging from 0.1 to 1000 uM) were coated onto 96-well plates and FLS adhesion to RGDS peptide-coated wells were compared to adhesion to GRGES peptide (Fig. 92? ). As expected, FLS adhered to RGDS peptide in a dose-dependent manner. Similarly, when SVVYGLR and SVVYGL peptides were coated onto the wells, FLS adhered to SVVYGLR peptide, but not SVVYGL in a dosedependent manner (Fig. 9C) . Extensive characterization of the two antibodies, Anti-OPN-R and Anti-OPN-L, by Western blot (Fig. 4) and ELISA ( Fig. 5 and Fig. 6 ) is indicative of the specificity of the antibodies for their respective antigens. Epitope mapping of OPN-R antibodies revealed that Anti-OPN-R, which was raised against SLAYGLR peptide, specifically binds to the four amino acids YGLR. On the other hand, Anti-OPN-L raised against SVVYGL recognizes the first valine and the YGL sequence. The fact that the C-terminal residues N-terminal to the thrombin / CPB cleavage site, namely leucine (in the case of Anti-OPN-L) and arginine (in the case of Anti-OPN-R) and their carboxyl groups are essential for antibody recognition (Fig. 7) , confirm that the antibodies would not recognize MMP3 and MMP9-cleaved OPN. Since the two metalloproteinases are known to cleave after glycine within the SVVYGLR sequence, cleavage with these metalloproteinases essentially destroys the Anti-OPN-R and Anti-OPN-L recognition sites. It should be noted, even though Anti-OPN-R and Anti-OPN-L specifically recognize the thrombin-cleaved and thrombin / CPB-cleaved OPN, they cannot distinguish whether these cleaved forms of OPN have been further cleaved by other proteases.
Once specificity of the antibodies were determined, they were used to investigate whether OPN-R and OPN-L could be detected from the RA synovial fluids. Synovial fluid OPN has not been characterized, but it is known that the protein is highly modified post-translationally. Therefore, it could be speculated that the glycosylation and phosphorylation patterns of OPN found in synovial fluid would be different from milk OPN and could possibly contribute to differential affinities of the antibodies for the two forms. Therefore, the initial attempt was to analyze the synovial fluid OPN by Western blot. However, due to the presence of high concentrations of albumin, immunoglobulins and rheumatoid factor in the synovial fluid samples which non-specifically reacted with the antibodies, Western blot analysis of synovial fluid OPN failed. Therefore, sandwich ELISA was used as the method of choice, to minimize non-specific interactions. In this way only osteopontin would bind to the Anti-OPN capture antibody on the plate and all else would be washed away, therefore, the chance of cross-reactivity with antibodies were minimized. However, in a Western blot setting where whole synovial fluid is run on a gel and all proteins are transferred onto a blot the chance of non-specific interactions are considerably higher.
Using the specific OPN-R and OPN-L ELISA, levels of both OPN-R and OPN-L were found to be significantly elevated within the rheumatic joints compared to their levels in OA and PsA joints, supporting the notion that thrombin cleavage of OPN and the subsequent cleavage of OPN-R into OPN-L by CPB occur within the rheumatic joints.
There was a wide range of full-length and cleaved OPN levels in the synovial fluids of RA patients compared to OA and PsA, ranging from undetectable to more than 50 ug/ml (Fig. 8A) . Such wide distribution of OPN level may be partly attributed to stage of disease, its severity, and the particular treatment regimen at time of synovial fluid collection. Therefore, further studies of the inflammatory state of the patients are necessary to understand the heterogeneity of OPN levels found in RA.
Contrary to previous published results (10) , in this study the median OPN-FL level of RA synovial fluids was not significantly higher compared to OA and PsA (Fig. 8A) . This finding may be partly explained by the small sample size, or by variations in the inflammatory stage of disease and treatment regimens of individual patients at time of fluid collection.
The ratio of cleaved OPNs (OPN-R and OPN-L) to OPN-FL in RA synovial fluid samples had a median value of 0.5, suggesting that almost half of the OPN within the rheumatic joint space has been cleaved into OPN-R and OPN-L (Fig. 8B) . On the contrary, the ratio of cleaved OPNs to OPN-FL in OA and PsA was significantly lower.
This finding is suggestive that the cleaved forms of OPN may play important roles in the pathogenesis of RA, but not OA and PsA.
Once it was established that cleaved OPNs are present at high levels in at least a subset of RA synovial fluids, the biological relevance of this finding was explored using cells from RA joints. The primary fibroblast-like synoviocytes (FLS) within the joint space express a4 (CD49d) on their surface (23) . On the other hand, thrombin-exposed Cterminal sequence SVVYGLR of OPN-R binds to the a4 subunit of a4(31 (18) .
Furthermore, data on integrin profile of fibroblast-like synoviocytes showed there is a 3-4 fold increased expression of cc4 in rheumatoid arthritic synovium compared to normal synovium (23) . This information along with the finding that FLS binds OPN-R preferentially when compared to OPN-FL and the doubly-cleaved OPN-L (Fig. 9A) , 
